Cognition Therapeutics (CGTX) Projected to Release Quarterly Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Cognition Therapeutics to announce earnings of ($0.07) per share and revenue of $5.30 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Cognition Therapeutics (NASDAQ:CGTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. On average, analysts expect Cognition Therapeutics to post ($0.30) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Cognition Therapeutics Trading Down 1.3%

Shares of NASDAQ CGTX opened at $0.75 on Thursday. Cognition Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.83. The firm’s 50-day moving average is $0.92 and its 200-day moving average is $1.08. The firm has a market capitalization of $71.23 million, a PE ratio of -4.41 and a beta of 1.80.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on CGTX shares. HC Wainwright restated a “buy” rating on shares of Cognition Therapeutics in a report on Monday, October 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, September 21st. Finally, Wall Street Zen cut shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $3.33.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.